Chemical Namefam-trastuzumab deruxtecan-nxki
Dosage FormInjectable (intravenous; 100 mg/vial)
Drug ClassMonoclonal antibodies
SystemFemale reproductive
CompanyDaiichi Sankyo Inc.
Approval Year2019


  • Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.2020New England Journal of Medicine